Form DEF 14A Sagent Pharmaceuticals, For: Jun 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c
May 3, 2016 7:34 AM EDTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.15), $0.16 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $67.3 million versus the consensus estimate of $74.3 million.
Sagents business plan for fiscal 2016 currently anticipates:
Net... More